Risk Factors for Metachronous Isolated Peritoneal Metastasis after Preoperative Chemotherapy and Potentially Curative Gastric Cancer Resection: Results from the CRITICS Trial
Authors:
- Irene A. CaspersICIrene A. Caspers
- Karolina SikorskaKSKarolina Sikorska
- Astrid E. SlagterASAstrid E. Slagter
- Romy M. van AmelsfoortRARomy M. van Amelsfoort
- Elma Meershoek-Klein KranenbargEKElma Meershoek-Klein Kranenbarg
- Cornelis J. H. van de VeldeCVCornelis J. H. van de Velde
- Pehr LindPLPehr Lind
- Marianne NordsmarkMNMarianne Nordsmark
- Edwin P. M. JansenEJEdwin P. M. Jansen
- Marcel VerheijMVMarcel Verheij
- Johanna W. van SandickJSJohanna W. van Sandick
- Annemieke CatsACAnnemieke Cats
Open Access
Abstract
Gastric cancer (GC) patients at high risk of developing peritoneal metastasis (PM) as a single site of metastasis after curative treatment may be candidates for adjuvant prophylactic strategies. Here we investigated risk factors for metachronous isolated PM in patients who were treated in the CRITICS trial (NCT00407186). Univariable and multivariable analyses on both metachronous isolated PM and ‘other events’, i.e., (concurrent) distant metastasis, locoregional recurrence or death, were performed using a competing risk model and summarized by cumulative incidences. Isolated PM occurred in 64 of the 606 (11%) included patients. Diffuse or mixed histological subtype, ypT4 tumor stage and LNhigh (ypN3 lymph node stage or a lymph node ratio >20%) were independent risk factors for isolated PM in both univariable and multivariable analyses. Likewise, LNhigh was an independent risk factor for ‘other events’. Patients with tumors who were positive for all three independent risk factors had the highest two-year cumulative incidence of 43% for isolated PM development. In conclusion, diffuse or mixed histological subtype, ypT4 and LNhigh were identified as independent risk factors for isolated PM in patients treated with preoperative chemotherapy followed by surgical resection. The combination of these factors may identify a subgroup that may benefit from PM-preventing treatment strategies.Keywords
This publication has 35 references indexed in Scilit:
- TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG/TROG/EORTC/NCIC CTG)BMC Cancer, 2015
- Incidence, time course and independent risk factors for metachronous peritoneal carcinomatosis of gastric origin – a longitudinal experience from a prospectively collected database of 1108 patientsBMC Cancer, 2015
- Rates and Patterns of Recurrence after Curative Intent Resection for Gastric Cancer: A United States Multi-Institutional AnalysisJournal of the American College of Surgeons, 2014
- GASTRICHIP: D2 resection and hyperthermic intraperitoneal chemotherapy in locally advanced gastric carcinoma: a randomized and multicenter phase III studyBMC Cancer, 2014
- Peritoneal carcinomatosis of gastric origin: A population‐based study on incidence, survival and risk factorsInternational Journal of Cancer, 2013
- Chemotherapy as palliative treatment for peritoneal carcinomatosis of gastric originActa Oncologica, 2013
- Risk factors of peritoneal recurrence in eso-gastric signet ring cell adenocarcinoma: Results of a multicentre retrospective studyEuropean Journal of Surgical Oncology, 2013
- Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS)BMC Cancer, 2011
- Evaluation of the 7th UICC TNM Staging System of Gastric CancerJournal of Gastric Cancer, 2011
- Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal CancerNew England Journal of Medicine, 2006